CVR: 39507501
DKK -543,530
Gross profit
Net result: DKK -1,212,924
Sandlykke A/S, HDJ & LEJ Invest ApS
1 more
CVR · view ownership and management
Director role ended: Hanne Damgaard Jensen
CVR · 22/06/2026
View the full event history
ROS Therapeutics ApS was a Danish company of the type Anpartsselskab based in Roskilde, founded in 2018. The company was registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Hanne Damgaard Jensen. The company is owned by Sandlykke A/S, HDJ & LEJ Invest ApS and ROS Therapeutics Holding ApS. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK -543,530 and a net result of DKK -1,212,924 compared with DKK -1,314,915 the year before. Equity in the 2025 report amounted to DKK -7,954,408.
Selskabets formål er at drive farmaceutisk virksomhed samt anden virksomhed, der står i forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -544 t. | -1.2 mio. | 602 t. | -8 mio. | 1 | |
| 202401/01/2024 – 31/12/2024 | -584 t. | -1.3 mio. | 1.3 mio. | -6.6 mio. | 1 | |
| 202301/01/2023 – 31/12/2023 | -678 t. | -1.2 mio. | 1.9 mio. | -5.3 mio. | 1 | |
| 202201/01/2022 – 31/12/2022 | -3.1 mio. | -3.4 mio. | 3.4 mio. | -4.1 mio. | 1 | |
| 202101/01/2021 – 31/12/2021 | -4.8 mio. | -4.4 mio. | 6.3 mio. | -758 t. | 1 | |
| 202001/01/2020 – 31/12/2020 | -2 mio. | -1.9 mio. | 10.2 mio. | 3.6 mio. | 1 | |
| 201901/01/2019 – 31/12/2019 | -2.1 mio. | -1.9 mio. | 5.1 mio. | 5 mio. | 0 |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringROS Therapeutics ApS is registered in the Danish CVR register with the status Under liquidation.
ROS Therapeutics ApS was founded on 23 April 2018.
ROS Therapeutics ApS was registered under the industry Fremstilling af farmaceutiske præparater (industry code 212000).
ROS Therapeutics ApS had 1 employee in 2018 according to the Danish CVR register.
ROS Therapeutics ApS is owned by Sandlykke A/S, HDJ & LEJ Invest ApS and ROS Therapeutics Holding ApS.
In 2025, ROS Therapeutics ApS reported a gross profit of DKK -543,530.
ROS Therapeutics ApS has published its annual report for 2025. Gross profit came to DKK -543,530, and the net result was DKK -1,212,924.
On June 23, 2026, ROS Therapeutics ApS entered liquidation.
As of June 22, 2026, Ulrik Spork has left the board of directors of ROS Therapeutics ApS.
As of June 22, 2026, Morten Amstrup Sandlykke has left the board of directors of ROS Therapeutics ApS.
As of June 22, 2026, Hanne Damgaard Jensen has left the board of directors of ROS Therapeutics ApS.
As of June 22, 2026, Ricki Boye has left the board of directors of ROS Therapeutics ApS.
As of June 22, 2026, Henrik Castenholm Fenger has left the board of directors of ROS Therapeutics ApS.
As of June 22, 2026, Hanne Damgaard Jensen is registered as liquidator of ROS Therapeutics ApS.
As of June 22, 2026, Hanne Damgaard Jensen has stepped down as adm. dir. of ROS Therapeutics ApS.
On June 22, 2026, ROS Therapeutics ApS entered liquidation.
As of August 15, 2025, BDO Statsautoriseret Revisionspartnerselskab has been appointed auditor of ROS Therapeutics ApS.
As of August 15, 2025, A/S PSE 17 NR. 1056 has stepped down as auditor of ROS Therapeutics ApS.
ROS Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -583,751, and the net result was DKK -1,314,915.
ROS Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -677,648, and the net result was DKK -1,152,395.
ROS Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -3,096,334, and the net result was DKK -3,350,372.
ROS Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -4,763,306, and the net result was DKK -4,381,494.
As of June 1, 2022, Henrik Castenholm Fenger has joined the board of directors of ROS Therapeutics ApS.
ROS Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK -2,037,635, and the net result was DKK -1,900,359.
As of October 2, 2020, Morten Amstrup Sandlykke has joined the board of directors of ROS Therapeutics ApS.
As of September 7, 2020, Sandlykke A/S is registered as an owner of ROS Therapeutics ApS with an ownership share of 10%.
As of September 7, 2020, HDJ & LEJ Invest ApS is registered as an owner of ROS Therapeutics ApS with an ownership share of 5%.
As of September 7, 2020, ROS Therapeutics Holding ApS is registered as an owner of ROS Therapeutics ApS with an ownership share of 50%.
As of June 29, 2020, A/S PSE 17 NR. 1056 has been appointed auditor of ROS Therapeutics ApS.
As of June 29, 2020, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of ROS Therapeutics ApS.
ROS Therapeutics ApS has published its annual report for 2019. Gross profit came to DKK -2,140,000, and the net result was DKK -1,883,000.
ROS Therapeutics ApS has published its interim report for the period April 23, 2018 – December 31, 2018.
As of May 3, 2019, Ricki Boye has joined the board of directors of ROS Therapeutics ApS.
As of May 3, 2019, Anker Gunvald Lundemose has left the board of directors of ROS Therapeutics ApS.
As of May 3, 2019, Mads Hartvig Clausen has left the board of directors of ROS Therapeutics ApS.
As of May 3, 2019, Jon Bondebjerg has left the board of directors of ROS Therapeutics ApS.
As of October 24, 2018, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ROS Therapeutics ApS.
As of October 12, 2018, Ulrik Spork has joined the board of directors of ROS Therapeutics ApS.
As of October 12, 2018, Hanne Damgaard Jensen has joined the board of directors of ROS Therapeutics ApS.
As of October 12, 2018, Christian Philip Hansen has left the board of directors of ROS Therapeutics ApS.
As of October 11, 2018, Ulrik Spork has left the board of directors of ROS Therapeutics ApS.
As of October 11, 2018, Hanne Damgaard Jensen has left the board of directors of ROS Therapeutics ApS.
As of August 27, 2018, Ulrik Spork has joined the board of directors of ROS Therapeutics ApS.
As of August 27, 2018, Anker Gunvald Lundemose has joined the board of directors of ROS Therapeutics ApS.
As of April 23, 2018, Hanne Damgaard Jensen has joined the board of directors of ROS Therapeutics ApS.
As of April 23, 2018, Christian Philip Hansen has joined the board of directors of ROS Therapeutics ApS.
As of April 23, 2018, Mads Hartvig Clausen has joined the board of directors of ROS Therapeutics ApS.
As of April 23, 2018, Jon Bondebjerg has joined the board of directors of ROS Therapeutics ApS.
As of April 23, 2018, Hanne Damgaard Jensen is registered as adm. dir. of ROS Therapeutics ApS.
ROS Therapeutics ApS was founded on April 23, 2018.
Companies in the same industry and area
